PLX241220C7500
- 0.00
- 0.000.00%
Protalix Biotherapeutics Newsroom
Protalix BioTherapeutics, Inc. (PLX) Q3 2024 Earnings Call Transcript Summary
Protalix BioTherapeutics Reports Profit In Q3; Announces Positive Phase 1 Data For PRX-115
Protalix BioTherapeutics Q3 24 Earnings Conference Call At 8:30 AM ET
Protalix Biotherapeutics | 10-Q: Q3 2024 Earnings Report
Protalix Biotherapeutics | 8-K: Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results
Earnings Flash (PLX) PROTALIX BIOTHERAPEUTICS Reports Q3 Revenue $18M
Protalix BioTherapeutics GAAP EPS of $0.03, Revenue of $17.96M
Protalix BioTherapeutics 3Q Net $3.24M >PBD.DU
Earnings Scheduled For November 14, 2024
Here's the Major Earnings Before the Open Tomorrow
Earnings Outlook For Protalix BioTherapeutics
Kepler Capital Remains a Buy on PLUXEE N.V. (PLX)
Earnings Preview: PLX to Report Financial Results Pre-market on November 14
Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024
Express News | Protalix BioTherapeutics To Present Data From Phase I Clinical Trial Of PRX-115 Recombinant PEGylated Uricase Product Candidate
Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024
Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Express News | Protalix BioTherapeutics Announced That It Has Repaid In Full Its 7.50% Senior Secured Convertible Promissory Notes Financed Entirely With Available Cash
Is Protalix BioTherapeutics, Inc. (PLX) The Best Rated Penny Stock To Buy According to Analysts?
Express News | Protalix BioTherapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q2 EPS Results